Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update.

Pharmacogenomics - 1 Jul 2007

Anglicheau Dany, Legendre Christophe, Beaune Philippe, Thervet Eric

Abstract excerpt

Among the immunosuppressive drugs currently used in solid-organ transplantation, the calcineurin inhibitors cyclosporine and tacrolimus, and the mammalian target of rapamycin inhibitors sirolimus and everolimus, may be difficult to use because of large interindividual variability in their pharmacokinetic characteristics and a narrow therapeutic index. The promise of pharmacogenetics and pharmacogenomics is to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Frameshift Mutation
Share to Cytochrome P-450 CYP3A
Share to HIV/AIDS drug development and treatment

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Immunosuppressive Agents

Share to Pharmacological Effects and Toxicity Studies

Share to Polymorphism, Genetic

Share to Polymorphism, Single Nucleotide

Share to Renal Transplantation Outcomes and Treatments

Source

Identifiers

PMID: 18240909
DOI: 10.2217/14622416.8.7.835

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update.PMID 18240909Read ↗

Use of Pharmacogenetics to Optimize Immunosuppressant Therapy in Kidney-Transplanted PatientsSemantic proximity Read ↗

CYP3A polymorphisms and immunosuppressive drugs in solid-organ transplantation.Semantic proximity Read ↗

Biotransformation enzymes and drug transporters pharmacogenetics in relation to immunosuppressive drugs: impact on pharmacokinetics and clinical outcome.Semantic proximity Read ↗

Pharmacogenetic biomarkers: cytochrome P450 3A5.Semantic proximity Read ↗

Impact of CYP3A4*1B and CYP3A5*3 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients.Semantic proximity Read ↗

The Pharmacogenetics of Calcineurin Inhibitors: One Step Closer Toward Individualized Immunosuppression?Semantic proximity Read ↗

Pharmacogenetics in solid organ transplantation: current status and future directions.Semantic proximity Read ↗

Use of pharmacogenetics to optimize immunosuppressive therapy.Semantic proximity Read ↗

Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients.Semantic proximity Read ↗

Pharmacogenetics of immunosuppressants: progress, pitfalls and promises.Semantic proximity Read ↗

Pharmacogenetics of immunosuppressant polymorphism of CYP3A5 in renal transplant recipients.Semantic proximity Read ↗

Current progress in pharmacogenetics and individualized immunosuppressive drug dosing in organ transplantation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.